It is going to take some months to launch the RXi-109 clinical trial. It would take a few more months before RXi will have solid findings in its progress reports.
To expect significant good news to drive RXi's share price up in the near future is unrealistic.
Though, more information on how the company finance its operations and more information on the clinical trial of the anit-scarring project would reduce heavy speculation and more serious investors who are willing to support the company.
If my other biotech investment turns out well next week, I plan to buy more RXi shares.
The weather is excellent here. So, I am going to enjoy it. Have a nice weekend!